Nothing Special   »   [go: up one dir, main page]

EA201890572A1 - Биофармацевтические композиции - Google Patents

Биофармацевтические композиции

Info

Publication number
EA201890572A1
EA201890572A1 EA201890572A EA201890572A EA201890572A1 EA 201890572 A1 EA201890572 A1 EA 201890572A1 EA 201890572 A EA201890572 A EA 201890572A EA 201890572 A EA201890572 A EA 201890572A EA 201890572 A1 EA201890572 A1 EA 201890572A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
biopharmaceutical compositions
biopharmaceutical
interleukin
treatment
Prior art date
Application number
EA201890572A
Other languages
English (en)
Other versions
EA037487B1 (ru
Inventor
Мирна А. Монк
Нрендра Б. Бам
Дженнифер Дэлли
Мишелль Спатара
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201890572(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Publication of EA201890572A1 publication Critical patent/EA201890572A1/ru
Publication of EA037487B1 publication Critical patent/EA037487B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Раскрытие относится к композициям для лечения заболеваний, опосредованных интерлейкином 5 (IL-5), и к связанным с ними способам.
EA201890572A 2015-08-24 2016-08-22 Биофармацевтические композиции EA037487B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02
PCT/IB2016/055012 WO2017033121A1 (en) 2015-08-24 2016-08-22 Biopharmaceutical compositions

Publications (2)

Publication Number Publication Date
EA201890572A1 true EA201890572A1 (ru) 2018-10-31
EA037487B1 EA037487B1 (ru) 2021-04-02

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890572A EA037487B1 (ru) 2015-08-24 2016-08-22 Биофармацевтические композиции

Country Status (22)

Country Link
US (10) US10870695B2 (ru)
EP (2) EP4056590A1 (ru)
JP (4) JP6821659B2 (ru)
KR (2) KR20240099511A (ru)
CN (5) CN116327921A (ru)
AU (1) AU2016311385C1 (ru)
BR (1) BR112018003741A2 (ru)
CA (1) CA2996088A1 (ru)
CL (1) CL2018000499A1 (ru)
CO (1) CO2018001840A2 (ru)
CR (1) CR20180115A (ru)
DO (1) DOP2018000057A (ru)
EA (1) EA037487B1 (ru)
IL (1) IL257539A (ru)
MA (1) MA42692A (ru)
MX (2) MX2018002319A (ru)
PE (1) PE20181176A1 (ru)
PH (1) PH12018500379A1 (ru)
TW (2) TWI750133B (ru)
UY (1) UY36868A (ru)
WO (1) WO2017033121A1 (ru)
ZA (1) ZA201801158B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2811518C1 (ru) * 2020-08-20 2024-01-12 Реджейнкор Биотех Ко., Лтд Il-5-связывающая молекула, способ ее получения и ее применение

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10870695B2 (en) 2015-08-24 2020-12-22 Glaxosmithkline Intellectual Property (No. 2) Limited Biopharmaceutical compositions comprising interleukin-5 antibody
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
JP7060906B2 (ja) 2016-12-23 2022-04-27 セファロン インコーポレイテッド 抗ｉｌ－５抗体
MX2019014105A (es) * 2017-05-26 2020-02-07 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y metodos relacionados.
EP3634467A4 (en) * 2017-06-06 2021-07-28 GlaxoSmithKline LLC BIOPHARMACEUTICAL COMPOSITIONS AND PROCEDURES FOR PEDIATRIC PATIENTS
BR112020005766A2 (pt) 2017-09-29 2020-10-13 Jiangsu Hengrui Medicine Co., Ltd. anticorpo il-5, fragmento de ligação ao antígeno do mesmo, e aplicação médica do mesmo
US11613571B2 (en) 2018-05-23 2023-03-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
BR112021019272A2 (pt) 2019-03-29 2022-01-04 Jiangsu Hengrui Medicine Co Composição farmacêutica contendo anticorpo contra il-5 e uso da mesma
CN115298218A (zh) * 2019-12-18 2022-11-04 特沙诺有限公司 生物药物组合物和相关方法
WO2023049803A1 (en) * 2021-09-22 2023-03-30 Sonoma Biotherapeutics, Inc. Il5ra cell surface markers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
PL194312B1 (pl) 1994-12-23 2007-05-31 Smithkline Beecham Corp Przeciwciało monoklonalne neutralizujące gryzoni,linia hybrydoma, humanizowane przeciwciało, region CDR ciężkiego łańcucha immunoglobuliny, region CDR lekkiego łańcucha immunoglobuliny, cząsteczki kwasu nukleinowego, przeciwciało chimeryczne, kompozycja farmaceutyczna, izolowana sekwencja kwasu nukleinowego, rekombinowany plazmid i komórka gospodarza oraz sposób wytwarzania humanizowanego przeciwciała i sposób wspomagania diagnostyki alergii
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
JP5528710B2 (ja) 2006-02-28 2014-06-25 オリガシス コーポレイション アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法
JP2010526087A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
CN104650235A (zh) 2007-11-30 2015-05-27 葛兰素集团有限公司 抗原结合构建体
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
MX2010010667A (es) 2008-03-28 2010-11-09 Glaxosmithkline Llc Metodos de tratamiento.
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
JP5212849B2 (ja) 2010-01-14 2013-06-19 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
EA029972B1 (ru) 2011-02-09 2018-06-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы получения полипептидных композиций
EA201391488A1 (ru) 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
US20140044727A1 (en) 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
US20160235667A1 (en) 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
CA2935532A1 (en) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
US10870695B2 (en) 2015-08-24 2020-12-22 Glaxosmithkline Intellectual Property (No. 2) Limited Biopharmaceutical compositions comprising interleukin-5 antibody

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2811518C1 (ru) * 2020-08-20 2024-01-12 Реджейнкор Биотех Ко., Лтд Il-5-связывающая молекула, способ ее получения и ее применение

Also Published As

Publication number Publication date
CO2018001840A2 (es) 2018-05-31
US20220185878A1 (en) 2022-06-16
US20220380452A1 (en) 2022-12-01
TW201722473A (zh) 2017-07-01
MX2024001617A (es) 2024-03-06
ZA201801158B (en) 2019-08-28
US20210340247A1 (en) 2021-11-04
JP2020033351A (ja) 2020-03-05
DOP2018000057A (es) 2018-03-15
EA037487B1 (ru) 2021-04-02
EP3341409A1 (en) 2018-07-04
UY36868A (es) 2017-03-31
CN116327923A (zh) 2023-06-27
US20200199219A1 (en) 2020-06-25
EP4056590A1 (en) 2022-09-14
US20240294629A1 (en) 2024-09-05
PH12018500379A1 (en) 2018-09-03
JP6821659B2 (ja) 2021-01-27
KR20180037275A (ko) 2018-04-11
US20240294628A1 (en) 2024-09-05
IL257539A (en) 2018-04-30
CN116474091A (zh) 2023-07-25
JP2022023049A (ja) 2022-02-07
TWI780988B (zh) 2022-10-11
PE20181176A1 (es) 2018-07-20
BR112018003741A2 (pt) 2018-09-25
US20240294630A1 (en) 2024-09-05
JP2018526369A (ja) 2018-09-13
MA42692A (fr) 2018-07-04
US11274148B2 (en) 2022-03-15
CR20180115A (es) 2018-04-12
US10870695B2 (en) 2020-12-22
TWI750133B (zh) 2021-12-21
US11459384B2 (en) 2022-10-04
JP2024123040A (ja) 2024-09-10
CN116327922A (zh) 2023-06-27
AU2016311385A1 (en) 2018-03-15
CN108137683A (zh) 2018-06-08
AU2016311385B2 (en) 2019-05-09
AU2016311385C1 (en) 2019-08-22
JP7463070B2 (ja) 2024-04-08
KR20240099511A (ko) 2024-06-28
TW202233238A (zh) 2022-09-01
US11286298B2 (en) 2022-03-29
US20180251539A1 (en) 2018-09-06
CA2996088A1 (en) 2017-03-02
US11299541B2 (en) 2022-04-12
US20210340246A1 (en) 2021-11-04
MX2018002319A (es) 2018-04-11
CN116327921A (zh) 2023-06-27
US20210332125A1 (en) 2021-10-28
CL2018000499A1 (es) 2018-07-06
WO2017033121A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
EA201890572A1 (ru) Биофармацевтические композиции
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
EA201790630A1 (ru) Способы получения рибозидов
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890204A1 (ru) Антибактериальные соединения
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201892147A1 (ru) Бициклические соединения
EA201890817A1 (ru) Кристаллические формы бета-никотинамида мононуклеотида
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201691940A1 (ru) Новые соединения
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
EA201691541A1 (ru) Новые анти-baff антитела
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM